MULti-TImepoint VElocity-selective Reconciled with Spatially-sElective (MULTIVERSE) ASL: Improving robustness to both shortened and prolonged arterial transit time
- PMID: 40384457
- PMCID: PMC12204808
- DOI: 10.1002/mrm.30540
MULti-TImepoint VElocity-selective Reconciled with Spatially-sElective (MULTIVERSE) ASL: Improving robustness to both shortened and prolonged arterial transit time
Abstract
Purpose: To improve the quantification of existing multi-timepoint arterial spin labeling (ASL) methods in estimating cerebral blood flow (CBF) and arterial transit time (ATT) for a wider range of ATTs.
Methods: MULti-TImepoint VElocity-selective Reconciled with Spatially-sElective (MULTIVERSE) ASL utilizes multi-delay pseudo-continuous (PC) ASL and velocity-selective (VS) ASL with spatially defined bolus, and joint fitting to estimate CBF and ATT. Numerical simulations were performed to evaluate the accuracy and precision of single-delay and multi-delay PCASL and VSASL, as well as the proposed MULTIVERSE ASL, in quantifying CBF and ATT across an extended range of ATTs. The CBF and ATT estimates between multi-delay PCASL, VSASL, and MULTIVERSE ASL were compared across healthy volunteers.
Results: Numerical simulations showed that the utility of MULTIVERSE ASL improved the accuracy and precision over an extended ATT range of up to 4000 ms. In vivo scans from healthy subjects demonstrated that MULTIVERSE ASL led to reduced uncertainty in CBF and ATT quantification compared to multi-post-labeling delay PCASL while maintaining comparable repeatability.
Conclusion: This novel and straightforward approach improves the accuracy and precision of the fitted CBF and ATT over an extended range of ATT, which is not possible with existing ASL methods. Brain scans from healthy subjects demonstrated the feasibility and reliability of the technique, highlighting the clinical potential of ASL-based perfusion mapping in various altered physiological and pathological conditions.
Keywords: MULTIVERSE ASL; arterial spin labeling (ASL); arterial transit time (ATT); bolus arrival time (BAT); bolus duration; cerebral blood flow; pseudo‐continuous ASL (PCASL); velocity‐selective ASL (VSASL).
© 2025 International Society for Magnetic Resonance in Medicine.
Similar articles
-
Evaluating cerebrovascular reactivity measured by velocity selective inversion arterial spin labeling with different post-labeling delays: The effect of fast flow.Magn Reson Med. 2024 Nov;92(5):2065-2073. doi: 10.1002/mrm.30166. Epub 2024 Jun 9. Magn Reson Med. 2024. PMID: 38852173
-
High-Fidelity MRI Assessment of Cerebral Perfusion in Healthy Neonates Less Than 1 Week of Age.J Magn Reson Imaging. 2025 Sep;62(3):737-748. doi: 10.1002/jmri.29740. Epub 2025 Feb 13. J Magn Reson Imaging. 2025. PMID: 39945520
-
Recommendations for quantitative cerebral perfusion MRI using multi-timepoint arterial spin labeling: Acquisition, quantification, and clinical applications.Magn Reson Med. 2024 Aug;92(2):469-495. doi: 10.1002/mrm.30091. Epub 2024 Apr 9. Magn Reson Med. 2024. PMID: 38594906 Free PMC article. Review.
-
Transformer-based deep learning denoising of single and multi-delay 3D arterial spin labeling.Magn Reson Med. 2024 Feb;91(2):803-818. doi: 10.1002/mrm.29887. Epub 2023 Oct 17. Magn Reson Med. 2024. PMID: 37849048 Free PMC article.
-
Prognostic Utility of Arterial Spin Labeling in Traumatic Brain Injury: From Pathophysiology to Precision Imaging.NeuroSci. 2025 Aug 4;6(3):73. doi: 10.3390/neurosci6030073. NeuroSci. 2025. PMID: 40843689 Free PMC article. Review.
References
-
- Alsop DC, Detre JA, Golay X, et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med. 2015;73(1):102–116. doi: 10.1002/mrm.25197 - DOI - PMC - PubMed
-
- Xu F, Xu C, Liu D, Zhu D, Lu H, Qin Q. Comparison of Velocity Selective ASL and PCASL with Phase-Contrast MRI for Measuring CO2-induced Cerebrovascular Reactivity. In: Proceedings of the 31st Annual Meeting of ISMRM. London, England, UK; 2022:4907.
MeSH terms
Substances
Grants and funding
- P41 EB031771/EB/NIBIB NIH HHS/United States
- EB031771/EB/NIBIB NIH HHS/United States
- K25 AG083114/AG/NIA NIH HHS/United States
- HL138182/National Heart and Lung Institute
- R01 HL144751/HL/NHLBI NIH HHS/United States
- AG083114/AG/NIA NIH HHS/United States
- CA282928/Division of Cancer Prevention, National Cancer Institute
- NS139369/NS/NINDS NIH HHS/United States
- P30 AG066507/AG/NIA NIH HHS/United States
- AG066507/AG/NIA NIH HHS/United States
- R01 NS139369/NS/NINDS NIH HHS/United States
- R01 CA282928/CA/NCI NIH HHS/United States
- R01 HL138182/HL/NHLBI NIH HHS/United States
- HL144751/National Heart and Lung Institute
- AG082243/AG/NIA NIH HHS/United States
- RF1 AG082243/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical